Prehabilitation prior to oncological resection for stage I-III pancreatic ductal andenocarcinoma, esophageal and gastric cancer – a prospective feasibility study

Prehabilitation prior to oncological resection for stage I-III pancreatic ductal andenocarcinoma, esophageal and gastric cancer – a prospective feasibility study - EPPIC

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00034212

Enrollment

148

Registered

2024-06-24

Start date

2024-08-14

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C25

Interventions

Group 1: Patients with pancreatic, oesophageal and gastric cancer who undergo a series of established standard prehabilitation measures prior to curative resection

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Clinical UICC (Union internationale contre le cancer) stage I-III at time of diagnosis (Pancreatic cancer, esophageal cancer, gastric cancer) - Scheduled for curative-intent therapy - Age > 18 years and capable of signing informed consent

Exclusion criteria

Exclusion criteria: - Clinical UICC stage IV

Design outcomes

Primary

Measure	Time frame
Severe postoperative complications (Clavien Dindo classification grade IIIA-IVB), evaluation until 90 days after surgery	—

Secondary

Measure	Time frame
Completion of prescribed curative-intent therapy (surgery and perioperative therapy), periop blood transfusion, length of hospital stay, physical fitness, toxicity events of perioperative therapy, dose reduction of perioperative therapy, quality of life, sarcopenia, chachexia, nutritional status, exocrine insufficiency, transfusion requirement, disease-free survival, overall survival, adherence to and feasibility of prehabilitation program for patients and caregivers	—

Measure

Time frame

Completion of prescribed curative-intent therapy (surgery and perioperative therapy), periop blood transfusion, length of hospital stay, physical fitness, toxicity events of perioperative therapy, dose reduction of perioperative therapy, quality of life, sarcopenia, chachexia, nutritional status, exocrine insufficiency, transfusion requirement, disease-free survival, overall survival, adherence to and feasibility of prehabilitation program for patients and caregivers

—

Countries

Germany

Contacts

Public ContactLouisa Bolm

Universitätsklinikum Schleswig-Holstein, Campus Lübeck

louisa.bolm@uksh.de0451-500-40100

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026